NasdaqGM:SGMTBiotechs
Why Sagimet Biosciences (SGMT) Is Up 7.7% After Denifanstat’s Phase 3 Acne Success And What's Next
Sagimet Biosciences recently reported that Ascletis Pharma’s Phase 3 trial of ASC40 (Denifanstat) for acne met all primary and secondary endpoints and was well-tolerated, with no serious adverse events observed.
The results highlight fatty acid synthase (FASN) inhibition as a potentially new way to treat acne, with findings slated for presentation at upcoming medical congresses and in scientific publications.
Next, we’ll examine how Denifanstat’s Phase 3 success in acne may influence Sagimet...